Virtu Financial LLC bought a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 4,695 shares of the company’s stock, valued at approximately $423,000.
Several other institutional investors have also recently added to or reduced their stakes in NBIX. Capital Investment Advisory Services LLC purchased a new stake in Neurocrine Biosciences in the second quarter worth $43,000. NEXT Financial Group Inc grew its holdings in shares of Neurocrine Biosciences by 89.8% in the second quarter. NEXT Financial Group Inc now owns 560 shares of the company’s stock worth $47,000 after purchasing an additional 265 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Neurocrine Biosciences by 70.5% in the second quarter. Tower Research Capital LLC TRC now owns 595 shares of the company’s stock worth $51,000 after purchasing an additional 246 shares during the last quarter. Flagship Harbor Advisors LLC purchased a new position in Neurocrine Biosciences in the 3rd quarter worth about $67,000. Finally, Golden State Wealth Management LLC increased its stake in Neurocrine Biosciences by 100.0% in the 2nd quarter. Golden State Wealth Management LLC now owns 1,000 shares of the company’s stock worth $84,000 after buying an additional 500 shares during the period. Hedge funds and other institutional investors own 97.13% of the company’s stock.
Shares of NBIX stock opened at $117.64 on Wednesday. The stock’s 50-day moving average is $106.19 and its 200 day moving average is $93.81. Neurocrine Biosciences, Inc. has a 1-year low of $64.72 and a 1-year high of $118.42. The company has a debt-to-equity ratio of 0.83, a current ratio of 7.08 and a quick ratio of 6.99. The company has a market cap of $10.83 billion, a P/E ratio of 534.73, a PEG ratio of 5.90 and a beta of 1.24.
In related news, insider Dimitri E. Grigoriadis sold 10,188 shares of the stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $100.34, for a total transaction of $1,022,263.92. Following the completion of the sale, the insider now owns 118,596 shares of the company’s stock, valued at $11,899,922.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Malcolm Lloyd-Smith sold 9,956 shares of the stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $90.85, for a total transaction of $904,502.60. The disclosure for this sale can be found here. Insiders sold a total of 46,131 shares of company stock worth $4,745,275 over the last 90 days. Company insiders own 4.30% of the company’s stock.
NBIX has been the subject of several research reports. ValuEngine cut shares of Neurocrine Biosciences from a “hold” rating to a “sell” rating in a research report on Thursday, November 14th. Royal Bank of Canada set a $118.00 target price on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a research report on Friday, September 6th. TheStreet raised shares of Neurocrine Biosciences from a “c+” rating to a “b” rating in a research note on Tuesday, November 19th. BidaskClub upgraded Neurocrine Biosciences from a “hold” rating to a “buy” rating in a report on Friday, November 8th. Finally, Piper Jaffray Companies increased their price objective on Neurocrine Biosciences from $111.00 to $116.00 in a research note on Tuesday, November 5th. One research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $105.72.
Neurocrine Biosciences Profile
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.
Read More: What is a short straddle?
Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.